Catherine Sebrié

Catherine Sebrié

Auto-generated profile, based on publicly available information

Catherine Sebrié

Imagerie par Résonance Magnétique Médicale et Multi-modalités (IR4M-UMR8081), Université Paris Sud, 91405, Orsay, France

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2009 in Nature Materials
Verified
Journal Article
Closed access
PDF file
PHPatricia Horcajada
Patricia Horcajada
TCTamim Chalati
Tamim Chalati
CSChristian Serre
Christian Serre
BGBrigitte Gillet
Brigitte Gillet
CSCatherine Sebrie
Catherine Sebrie
Ruxandra GrefRuxandra Gref
Ruxandra Gref

26 February 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFayçal Guedj
Fayçal Guedj
CSCatherine Sébrié
Catherine Sébrié
Isabelle RivalsIsabelle Rivals
Isabelle Rivals
ALAurelie Ledru
Aurelie Ledru
EPEvelyne Paly
Evelyne Paly
JDJean M. Delabar
Jean M. Delabar
Individuals with partial HSA21 trisomies and mice with partial MMU16 trisomies containing an extra copy of the DYRK1A gene present various alterations in brain morphogenesis. They present also learning impairments modeling those encountered in Down syndrome. Previous MRI and histological analyses of a transgenic mice generated using a human YAC construct that contains five genes including DYRK1A reveal that DYRK1A is involved, during development, in the control of brain volume and cell density of specific brain regions. Gene dosage correction induces a rescue of the brain volume alterations. DYRK1A is also involved in the control of synaptic plasticity and memory consolidation. Increased gene dosage results in brain morphogenesis defects, low BDNF levels and mnemonic deficits in these mice. Epigallocatechin gallate (EGCG) — a member of a natural polyphenols family, found in great amount in green tea leaves — is a specific and safe DYRK1A inhibitor. We maintained control and transgenic mice overexpressing DYRK1A on two different polyphenol-based diets, from gestation to adulthood. The major features of the transgenic phenotype were rescued in these mice.

31 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
yolanda prezadoyolanda prezado
yolanda prezado
GJGregory Jouvion
Gregory Jouvion
DHDavid Hardy
David Hardy
APAnnalisa Patriarca
Annalisa Patriarca
CNCatherine Nauraye
Catherine Nauraye
FPFrederic Pouzoulet
Frederic Pouzoulet
Proton minibeam radiation therapy (pMBRT) is a novel strategy for minimizing normal tissue damage resulting from radiotherapy treatments. This strategy partners the inherent advantages of protons for radiotherapy with the gain in normal tissue preservation observed upon irradiation with narrow, spatially fractionated beams. In this study, whole brains (excluding the olfactory bulb) of Fischer 344 rats (n = 16) were irradiated at the Orsay Proton Therapy Center. Half of the animals received standard proton irradiation, while the other half were irradiated with pMBRT at the same average dose (25 Gy in one fraction). The animals were followed-up for 6 months. A magnetic resonance imaging (MRI) study using a 7-T small-animal MRI scanner was performed along with a histological analysis. Rats treated with conventional proton irradiation exhibited severe moist desquamation, permanent epilation and substantial brain damage. In contrast, rats in the pMBRT group exhibited no skin damage, reversible epilation and significantly reduced brain damage; some brain damage was observed in only one out of the eight irradiated rats. These results demonstrate that pMBRT leads to an increase in normal tissue resistance. This net gain in normal tissue sparing can lead to the efficient treatment of very radio-resistant tumours, which are currently mostly treated palliatively.

11 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
yolanda prezadoyolanda prezado
yolanda prezado
MSM. Dos Santos
M. Dos Santos
WGW. Gonzalez
W. Gonzalez
GJG. Jouvion
G. Jouvion
CGConsuelo Guardiola
Consuelo Guardiola
FPF. Pouzoulet
F. Pouzoulet
Minibeam radiation therapy (MBRT) is an innovative synchrotron radiotherapy technique able to shift the normal tissue complication probability curves to significantly higher doses. However, its exploration was hindered due to the limited and expensive beamtime at synchrotrons. The aim of this work was to develop a cost-effective equipment to perform systematic radiobiological studies in view of MBRT. Tumor control for various tumor entities will be addressable as well as studies to unravel the distinct biological mechanisms involved in normal and tumor tissues responses when applying MBRT. With that aim, a series of modifications of a small animal irradiator were performed to make it suitable for MBRT experiments. In addition, the brains of two groups of rats were irradiated. Half of the animals received a standard irradiation, the other half, MBRT. The animals were followed-up for 6.5 months. Substantial brain damage was observed in the group receiving standard RT, in contrast to the MBRT group, where no significant lesions were observed. This work proves the feasibility of the transfer of MBRT outside synchrotron sources towards a small animal irradiator.

6 October 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
MPMarine Poittevin
Marine Poittevin
PBPhilippe Bonnin
Philippe Bonnin
CPCynthia Pimpie
Cynthia Pimpie
LRLéa Rivière
Léa Rivière
CSCatherine Sebrié
Catherine Sebrié
NKNathalie Kubis
Nathalie Kubis
Diabetes increases the risk of stroke by three, increases related mortality, and delays recovery. We aimed to characterize functional and structural alterations in cerebral microvasculature before and after experimental cerebral ischemia in a mouse model of type 1 diabetes. We hypothesized that preexisting brain microvascular disease in patients with diabetes might partly explain increased stroke severity and impact on outcome. Diabetes was induced in 4-week-old C57Bl/6J mice by intraperitoneal injections of streptozotocin (60 mg/kg). After 8 weeks of diabetes, the vasoreactivity of the neurovascular network to CO2 was abolished and was not reversed by nitric oxide (NO) donor administration; endothelial NO synthase (eNOS) and neuronal NO synthase (nNOS) mRNA, phospho-eNOS protein, nNOS, and phospho-nNOS protein were significantly decreased; angiogenic and vessel maturation factors (vascular endothelial growth factor a [VEGFa], angiopoietin 1 (Ang1), Ang2, transforming growth factor-β [TGF-β], and platelet-derived growth factor-β [PDGF-β]) and blood-brain barrier (BBB) occludin and zona occludens 1 (ZO-1) expression were significantly decreased; and microvessel density was increased without changes in ultrastructural imaging. After permanent focal cerebral ischemia induction, infarct volume and neurological deficit were significantly increased at D1 and D7, and neuronal death (TUNEL+/NeuN+ cells) and BBB permeability (extravasation of Evans blue) at D1. At D7, CD31+/Ki67+ double-immunolabeled cells and VEGFa and Ang2 expression were significantly increased, indicating delayed angiogenesis. We show that cerebral microangiopathy thus partly explains stroke severity in diabetes.

15 September 2008 in Cerebral Cortex
Verified
Journal Article
Open access
PDF file
RMR. Miranda
R. Miranda
CSC. Sebrie
C. Sebrie
JDJ. Degrouard
J. Degrouard
BGB. Gillet
B. Gillet
DJD. Jaillard
D. Jaillard
CVCyrille Vaillend
Cyrille Vaillend
Dystrophin is a cytoskeletal membrane-bound protein expressed in both muscle and brain. Brain dystrophin is thought to be involved in the stabilization of γ-aminobutyric acid (GABA)A-receptor (GABAA-R)clusters in postsynaptic densities (PSDs) at inhibitory synapses onto pyramidal cells, and its loss has been linked to cognitive impairments in Duchenne muscular dystrophy. Dystrophin-deficient mdx mice have learning deficits and altered synaptic plasticity in cornu ammonis (CA1) hippocampus, but the possibility that altered synapse morphology or distribution may underlie these alterations has not been examined. Here we used in vivo magnetic resonance imaging and histological analyses to assess brain volumetric and cytoarchitectonic abnormalities and quantitative electron microscopy to evaluate the density and ultrastructure of CA1 hippocampal synapses in mdx mice. We found that mdx mice have increased density of axodendritic symmetric inhibitory synapses and larger PSDs in perforated asymmetric excitatory synapses in the proximal, but not distal, CA1 apical dendrites that normally express dystrophin, in the absence of gross brain malformations. Data are discussed in light of the known molecular and neurophysiological alterations in mdx mice. We suggest that increased inhibitory synapse density reflects tenuous compensation of altered clustering of α2 subunit–containing GABAA-Rs in CA1 dendrites, whereas increased PSD length in perforated synapses suggests secondary alterations in excitatory synapse organization associated with enhanced synaptic excitation.